The main purpose of LUSARA is research. Work at the lab is focused on the issue of bacterial resistance to antibiotics.
At LUSARA we believe that research must be primarily guided by curiosity, and not by marketing, impact or competitivity criteria.
We are not related in any way with governmental institutions, federal nor local, and we do not get public financing for research.
The research laboratory is equiped to perform microbiology and molecular biology projects. It has centrifugues, incubators, balances, electrophoresis equipment (including pulsed fields and acrylamide sequencing), electroporation, PCR, nucleic acid detection by hybridization, laminar flow hood, ultrafreezers (-70C and LN2) and a dark room.
On the prevalence of antibiotic resistance and factors that affect it: |
||
| NCBI | COPY |
Amábile Cuevas CF et al. (2001) Clin Infect Dis 32(suppl1):S30-2 |
| NCBI | COPY |
Díaz-Mejía JJ et al. (2002) FEMS Microbiol Lett 217:173-6 |
| NCBI | COPY |
López H et al. (2002) Rev Esp Quimioter 15:325-34 |
| NCBI | COPY |
Delissalde F et al (2004) Int J Antimicrob Agents 24:405-8 |
| NCBI | COPY |
Rosas I et al (2006) Int J Hyg Environ Health 209:461-70 |
| NCBI | COPY |
Díaz-Mejía et al (2008) Microbiology 154:94-102 |
| NCBI | COPY |
Arredondo-García JL et al. (2008) J Infect Devel Ctries 2:350-3 |
| NCBI | COPY |
Arredondo-García JL et al. (2009) J Infect Devel Ctries 3:398-401 |
| COPY |
Amábile-Cuevas CF et al. (2009) Rev Panam Infectol 11:31-6 |
|
| NCBI | COPY |
Amábile-Cuevas CF et al (2010) J Appl Microbiol 108:158-62 |
| NCBI | COPY |
Arredondo-García JL et al (2011) J Infect Devel Ctries 5:119-22 |
| NCBI | COPY |
Amábile-Cuevas CF et al (2013) J Infect Chemother 19:1135-1140 |
| NCBI | COPY |
Cristóbal-Azkarate J et al (2014) PLoS One 9:e107719 |
| NCBI | COPY |
Kurenbach B et al (2015) mBio 6:e00009-15 |
| NCBI | COPY |
Rosas I et al (2015) Curr Microbiol 71:490-495 |
| NCBI | COPY | Amábile-Cuevas CF (2016) Nature 533:439 |
| NCBI | COPY | Laxminarayan L et al (2016) Lancet 388:218-220 |
| NCBI | COPY | Amábile-Cuevas CF (2017) Microb Drug Resist 23:32-36 |
On clinical trials and the use of antibiotics: |
||
| NCBI | COPY |
Arredondo-García JL et al. (2004) J Antimicrob Chemother 54:840-3 |
| NCBI | COPY |
Urueta-Robledo J et al. (2006) Resp Med 100:1504-11 |
| NCBI | COPY |
Arrieta JR et al. (2007) Am J Otolaryngol 28:78-82 |
| NCBI | COPY |
Vick-Fragoso R et al. (2009) Infection 37:407-17 |
| NCBI | COPY |
Amábile-Cuevas CF et al. (2011) J Antimicrob Chemother 66:1652-3 |
| NCBI | COPY |
Levy-Hara G et al. (2011) Front Microbiol 2:230 |
| COPY |
Amábile-Cuevas CF (2012) Chemother J 21:39-40 |
|
| NCBI | COPY | Levy Hara G et al (2016) Int J Antimicrob Agents 48:239-246 |
On the effect of ascorbate upon plasmids: |
||
| NCBI | COPY |
Amábile Cuevas CF (1988) Mutat Res 207:107-9 |
| NCBI | COPY |
Amábile-Cuevas CF et al. (1991) Mutat Res 264:119-25 |
On the response of E. coli to superoxide stress: |
||
| NCBI | COPY |
Fuentes AM et al. (1997) FEMS Microbiol Lett 154:385-8 |
| NCBI | COPY |
Fuentes AM et al. (1998) Microbiology 144:1731-6 |
| NCBI | COPY |
Jiménez-Arribas G et al. (2001) FEMS Microbiol Lett195: 175-7 |
| NCBI | COPY |
Fuentes AM et al. (2001) FEMS Microbiol Lett 201:271-5 |
On antimicrobial activity of novel pyridines: |
|
| COPY |
Toscano RA et al. (1997) Chem Pharm Bull 45:957-61 |
| COPY |
Toscano RA et al. (2000) Heteroatom Chem 11:308-12 |
Methods: |
||
| NCBI | COPY |
Amábile-Cuevas CF (2013) J Global Antimicrob Resist 1:17-21 |
“Ivory tower” research benefits only the researcher. Despite not having any kind of public financing, at LUSARA we believe that education is the main product of research.
Therefore, we devote a sustantial effort to education, including courses, conferences and the formation of new researchers.
We also have an extensive record of books and reviews, serving specialized readers with integrating views and approaches; and articles in general-readership magazines, reaching the lay public.
Our laboratory housed several undergraduate and graduate theses projects, from the Universidad Iberoamericana, and the School of Biological Sciences and the School of Medicine and Homeopathy of the National Polythecnic Institute.
Although we are no longer receiving students, theses projects from other institutions have been supported in different ways.
Most financial resources that LUSARA devotes to research and education, come from services offered to pharmaceutical companies. We are especially able to communicate molecular, biochemical or pharmacological aspects of a product to the medical community, in a comprehensible and usable way. We have reached virtually all medical specialties with conferences, literature or multimedia materials. The laboratory has also been involved in clinical or in vitro trials involving antibiotics.
At our microbiology/molecular biology laboratory, we have provided support for clinical trials, as well as performed in vitro research projects. Among the later, we developed an HCV-HBV viral-load assessing method (before one was approved by FDA). Also, we have carried out susceptibility surveillance projects for cefditoren, cefdinir, ceftibuten, ciprofloxacin, colistin, ertapenem, isepamicin, moxifloxacin, nitrofurantoin, tigecycline and voriconazole. Some of them have been published in international journals.
On the other hand, most of the phase-II and phase-III clinical trials done in Mexico, leading to the licensing of moxifloxacin, were supported by LUSARA’s lab services. We were also involved in clinical trials for ciprofloxacin (phase III), faropenem (fase II) and nitrofurantoin (post-marketing).